Mycenax Biotech Inc. (TPEX:4726)

Taiwan · Delayed Price · Currency is TWD

26.00

-0.45 (-1.70%)

At close: Jul 8, 2026

-31.58% (1Y)

Market Cap	5.39B -33.5%
Revenue (ttm)	815.34M +12.4%
Net Income	-436.48M
EPS	-2.14
Shares Out	207.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	125,248
Open	26.45
Previous Close	26.45
Day's Range	26.00 - 26.80
52-Week Range	23.95 - 40.80
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Mycenax Biotech

Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company’s services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, and quality services. It also offers bispecific antibody production, and... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2001

Employees 387

Stock Exchange Taipei Exchange

Ticker Symbol 4726

Full Company Profile

Financial Performance

In 2025, Mycenax Biotech's revenue was 740.24 million, an increase of 8.23% compared to the previous year's 683.92 million. Losses were -448.63 million, -3.96% less than in 2024.

Financial Statements